PMID- 33440348
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 1945-4589 (Electronic)
IS  - 1945-4589 (Linking)
VI  - 13
IP  - 2
DP  - 2021 Jan 13
TI  - Multiwalled carbon nanotubes co-delivering sorafenib and epidermal growth factor 
      receptor siRNA enhanced tumor-suppressing effect on liver cancer.
PG  - 1872-1882
LID - 10.18632/aging.103905 [doi]
AB  - OBJECTIVE: This study aimed to investigate the effects of multiwalled carbon 
      nanotubes (MWNTs) co-delivering sorafenib (Sor) and epidermal growth factor 
      receptor (EGFR) siRNA (MWNT/Sor/siRNA) on tumor growth in liver cancer (LC). 
      RESULTS: MWNT/Sor/siRNA was proved to possess increased Sor release, high siRNA 
      stability, and enhanced cellular uptake. In addition, MWNT treatment has few 
      effects on cell proliferation and apoptosis in HepG2 cells; however, 
      MWNT/Sor/siRNA treatment significantly inhibited clone number and induced cell 
      apoptosis, which shows a more favorable antitumor effect than MWNT/Sor and free 
      Sor and free siRNA in HepG2 cells. Moreover MWNT/Sor/siRNA treatment has the most 
      significant antitumor effect in vivo. CONCLUSIONS: MWNT/Sor/siRNA exhibited a 
      superior antitumor effect in vitro and in vivo. METHODS: The MWNT/Sor and 
      MWNT/Sor/siRNA were prepared, and then the morphologies of MWNT/Sor/siRNA were 
      analyzed. In vitro Sor release assay, siRNA stability and cellular uptake of 
      MWNT/Sor/siRNA were performed as well. Next, the effects of MWNT, free Sor, free 
      siRNA, MWNT/Sor and MWNT/Sor/siRNA were evaluated by colony-forming assay, and 
      cell apoptosis assay in HepG2 cells. Meanwhile, the level of EGFR and proteins 
      associated with apoptosis was tested. Furthermore, the anti-tumor effects of 
      MWNT/Sor/siRNA on LC xenograft mice were also unraveled.
FAU - Wen, Zhili
AU  - Wen Z
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Feng, Yuliang
AU  - Feng Y
AD  - Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
FAU - Hu, Youwen
AU  - Hu Y
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Lian, Lingyan
AU  - Lian L
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Huang, Hongyan
AU  - Huang H
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Guo, Li
AU  - Guo L
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Chen, Shanwen
AU  - Chen S
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Yang, Qian
AU  - Yang Q
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Zhang, Moran
AU  - Zhang M
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Wan, Lijun
AU  - Wan L
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Xu, Kedong
AU  - Xu K
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Degejirifu
AU  - Degejirifu
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Yan, Xiaohua
AU  - Yan X
AD  - Department of Biochemistry and Molecular Biology, School of Basic Medical 
      Sciences, Nanchang University, Nanchang, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210113
PL  - United States
TA  - Aging (Albany NY)
JT  - Aging
JID - 101508617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Nanotubes, Carbon)
RN  - 0 (RNA, Small Interfering)
RN  - 9ZOQ3TZI87 (Sorafenib)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/administration & dosage/*therapeutic use
MH  - Apoptosis/drug effects
MH  - Cell Proliferation/drug effects
MH  - *Drug Delivery Systems
MH  - ErbB Receptors/*genetics/metabolism
MH  - Hep G2 Cells
MH  - Humans
MH  - Liver/drug effects/metabolism
MH  - Liver Neoplasms/*drug therapy/genetics
MH  - Mice
MH  - Mice, Nude
MH  - *Nanotubes, Carbon
MH  - Neoplasm Transplantation
MH  - RNA, Small Interfering/administration & dosage/*therapeutic use
MH  - Sorafenib/administration & dosage/*therapeutic use
PMC - PMC7880368
OTO - NOTNLM
OT  - epidermal growth factor receptor
OT  - liver cancer
OT  - multiwalled carbon nanotubes
OT  - sorafenib
COIS- CONFLICTS OF INTEREST: The author reports no conflicts of interest in this work.
EDAT- 2021/01/14 06:00
MHDA- 2021/05/11 06:00
PMCR- 2021/01/31
CRDT- 2021/01/13 20:09
PHST- 2020/05/02 00:00 [received]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2021/01/14 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
PHST- 2021/01/13 20:09 [entrez]
PHST- 2021/01/31 00:00 [pmc-release]
AID - 103905 [pii]
AID - 10.18632/aging.103905 [doi]
PST - ppublish
SO  - Aging (Albany NY). 2021 Jan 13;13(2):1872-1882. doi: 10.18632/aging.103905. Epub 
      2021 Jan 13.